Sera Prognostics Inc (SERA) - Net Assets
Based on the latest financial reports, Sera Prognostics Inc (SERA) has net assets worth $82.18 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($108.12 Million) and total liabilities ($25.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Sera Prognostics Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $82.18 Million |
| % of Total Assets | 76.01% |
| Annual Growth Rate | 34.25% |
| 5-Year Change | 1525.95% |
| 10-Year Change | N/A |
| Growth Volatility | 1861.57 |
Sera Prognostics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Sera Prognostics Inc's net assets have evolved over time, based on quarterly financial data. Also explore SERA current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Sera Prognostics Inc (2019–2024)
The table below shows the annual net assets of Sera Prognostics Inc from 2019 to 2024. For live valuation and market cap data, see Sera Prognostics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $47.80 Million | -31.86% |
| 2023-12-31 | $70.16 Million | -29.09% |
| 2022-12-31 | $98.94 Million | -28.59% |
| 2021-12-31 | $138.56 Million | +4613.06% |
| 2020-12-31 | $2.94 Million | -73.17% |
| 2019-12-31 | $10.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sera Prognostics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16818300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.01% |
| Other Comprehensive Income | $60.00K | 0.13% |
| Other Components | $327.53 Million | 685.17% |
| Total Equity | $47.80 Million | 100.00% |
Sera Prognostics Inc Competitors by Market Cap
The table below lists competitors of Sera Prognostics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fluoguide AS
ST:FLUO
|
$71.96 Million |
|
Sentelic Corp
TWO:4945
|
$71.98 Million |
|
Tainet Communication System
TWO:4905
|
$72.00 Million |
|
Cosmax Nbt Inc
KQ:222040
|
$72.02 Million |
|
COWELL FASHION Co.Ltd
KQ:033290
|
$71.85 Million |
|
ELUON Corporation
KQ:065440
|
$71.84 Million |
|
KENERGY
KLSE:0307
|
$71.81 Million |
|
HEMARAJ INDUSTRIAL PROPERTY AND LEASEHOLD FUND
BK:HPF
|
$71.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sera Prognostics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 70,158,000 to 47,803,000, a change of -22,355,000 (-31.9%).
- Net loss of 32,898,000 reduced equity.
- Other comprehensive income increased equity by 75,000.
- Other factors increased equity by 10,468,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-32.90 Million | -68.82% |
| Other Comprehensive Income | $75.00K | +0.16% |
| Other Changes | $10.47 Million | +21.9% |
| Total Change | $- | -31.86% |
Book Value vs Market Value Analysis
This analysis compares Sera Prognostics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.16x to 1.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.61 | $1.91 | x |
| 2020-12-31 | $0.16 | $1.91 | x |
| 2021-12-31 | $4.50 | $1.91 | x |
| 2022-12-31 | $3.20 | $1.91 | x |
| 2023-12-31 | $2.25 | $1.91 | x |
| 2024-12-31 | $1.44 | $1.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sera Prognostics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -68.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42724.68%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.52x
- Recent ROE (-68.82%) is above the historical average (-169.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -150.79% | -45891.67% | 0.00x | 2.12x | $-17.62 Million |
| 2020 | -675.10% | -79392.00% | 0.00x | 5.03x | $-20.14 Million |
| 2021 | -25.27% | -42693.90% | 0.00x | 1.06x | $-48.87 Million |
| 2022 | -44.66% | -16487.31% | 0.00x | 1.18x | $-54.08 Million |
| 2023 | -51.66% | -11843.79% | 0.00x | 1.36x | $-43.26 Million |
| 2024 | -68.82% | -42724.68% | 0.00x | 1.52x | $-37.68 Million |
Industry Comparison
This section compares Sera Prognostics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sera Prognostics Inc (SERA) | $82.18 Million | -150.79% | 0.32x | $71.87 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel bl… Read more